Corstrata Foot Ulcer Prevention Solution Named Among Semifinalists For T1D Exchange 2018 Diabetes Innovation Challenge

Share Article

Corstrata provides new tech empowered diabetic foot ulcer prevention to improve patient lives.

CORSTRATA, a provider of digital healthcare IT solutions and services for wound management, announced today that the company’s Diabetic Foot Ulcer & Amputation Prevention solution was named as a semifinalist in the T1D Exchange 2018 Diabetes Innovation Challenge. Corstrata was one of 30 semifinalists chosen from academic researchers and early stage companies from around the world that submitted entries for solutions to support advanced diabetes care. T1D Exchange is a nonprofit research and collaboration organization dedicated to accelerating novel treatments to improve the care of people living with type 1 diabetes (T1D).

Diabetic foot ulcers (DFUs) are a common, limb-threatening, and expensive complication of diabetes. Of the 29M people with diabetes in the U.S., 1.7M suffer with one or more DFUs annually and 80K of these diabetics ultimately require an amputation. The risk of death at 5 years for DFU patients is 2.5 times as high as the risk for a patient with diabetes without a foot ulcer.

Corstrata offers a technology-enabled care management solution for diabetics at risk for formation of costly diabetic foot ulcers and related amputations. Using a “smart” mat to detect potential ulcers,
Corstrata’s wound specialists engage with the patient through a mobile engagement app for timely intervention and prevention of ulcers. Corstrata’s Diabetic Foot Ulcer & Amputation Prevention Program serves as an outsourced end-to-end technology-enabled solution for value-based organizations and payers.

The program is designed to help with:

  • High-Risk Patient Identification
  • Program Enrollment
  • Daily Monitoring
  • Timely Intervention for Prevention
  • Self-Management

Corstrata’s Director of Clinical Services, Myra Varnado, BS, RN, CWON, CFCN, is also a noted industry expert on the Diabetic Foot and the primary author of the Wound, Ostomy and Continence Nurses’ Clinical Practice Guideline: “Management of Wounds in Patients with Lower Extremity Neuropathic Disease”. She previously served as the Diabetes Foot Program Coordinator for the LSU Health Sciences Center that included five remote telemedicine clinics focused on the prevention and management of patients with diabetic foot ulcers.

“We are honored to have Corstrata’s innovative, tech-empowered Foot Ulcer and Amputation Prevention solution chosen as a semifinalist for the T1D Exchange 2018 Diabetes Challenge,” said Katherine Piette, Chief Executive Officer and Founder, Corstrata. “Our mission is to advance wound prevention and care utilizing the most effective solutions available. Combined with our deep clinical expertise in wound management, including diabetic foot ulcer prevention, Corstrata is uniquely positioned to be a leader in use of evidence-based care to improve the lives of patients everywhere.”

The Diabetes Innovation Challenge will select first, second and third prize winners who will receive a total of $250,000 in cash and in-kind support for implementation of their solutions. A People’s Choice Award will also be awarded with People’s Choice voting being open March 23 – May 19.

As a semifinalist, Corstrata will present a poster depicting its solution at a public event on May 21, 2018, at the Royal Sonesto Boston in Cambridge, MA. Finalists will be announced in early April 2018. As part of the Challenge, each finalist will make a formal, in-person presentation of their proposal to an expert panel of judges at the same public event. Winners will be announced following the presentations.

For more information and to cast your People’s Choice vote, visit https://t1dexchange.org/pages/events/diabetes-innovation-challenge/

About Corstrata
Corstrata was founded in 2015 by two passionate healthcare experts with the goal of improving access to technology enabled, evidence-based care for patients with chronic wounds, which currently costs the U.S. $33B annually. Home health agencies, hospices, self-funded employers, clinically integrated networks of doctors and related practitioners (CINs), and third-party payers (Medicare Advantage, Medicaid MCOs) can benefit from Corstrata’s unique combination of professional expertise, digital technologies and telemedicine to treat wound patients and support practitioners anywhere, any time. The company delivers a Comprehensive Wound Care Management Program, Wound Patient Consultations, and specific services such as program, policy and procedure assessment, formulary design, treatment guidelines assessment, wound documentation review, and practitioner education. Wound program development is available for Pressure Injury (Ulcer) Prevention and Management, Diabetic Foot Ulcer Prevention and Management, Ostomy Care and Management, and Palliative Wound Management. For more information about Corstrata, visit http://www.corstrata.com.

Press Contact:
Katherine Piette
katherine.piette@corstrata.com
912-663-0958

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Katherine Piette
Corstrata
+1 912-663-0958
Email >
@Corstrata
since: 06/2015
Follow >
Visit website

Media

Corstrata logo